Can Morphine Help Protect the Brain against HIV Neurotoxicity and Cognitive Impairment?

Morphine, a drug derived from opium poppies that relieves pain and often triggers addiction, may help protect the brain from damage due to HIV by interfering with the virus' ability to enter cells, according to a study in mice reported last week at the annual meeting of the Society of NeuroImmune Pharmacology. The researchers emphasized that people should not use morphine or similar drugs like heroin to protect the brain, but suggested these findings may offer clues for designing future therapies to prevent neurocognitive impairment in people with HIV.

Below is a press release from Georgetown University Medical Center describing the research.

Drug Shared by Addicts Seems to Protect
against HIV Brain Dementia

Could heroin hold the clues for a new protective agent?

Washington, DC -- April 15, 2010 -- To their surprise, researchers at Georgetown University Medical Center (GUMC) have discovered that morphine (a derivate of the opium poppy that is similar to heroin) protects rat neurons against HIV toxicity -- a finding they say might help in the design of new neuroprotective therapies for patients with the infection.

The discovery, being presented at the annual meeting of the Society of NeuroImmune Pharmacology, also helps explain why a subset of people who are heroin abusers and become infected with HIV through needle sharing don't develop HIV brain dementia. This brain disorder includes cognitive and motor abnormalities, anxiety and depression.

"We believe that morphine may be neuroprotective in a subset of people infected with HIV," says the study's lead investigator, Italo Mocchetti, PhD, professor of neuroscience at GUMC. "That is not to say that people should use heroin to protect themselves -- that makes no medical sense at all -- but our findings gives us ideas about designing drugs that could be of benefit."

"Needless to say we were very surprised at the findings," he added. "We started with the opposite hypothesis -- that heroin was going to destroy neurons in the brain and lead to HIV dementia."

The researchers conducted the study because they knew that a number of HIV-positive people are also heroin abusers, and because of that, some are at high risk of developing neurological complications from the infection. Others, however, never develop these cognitive problems, Mocchetti says.

Because little is known about the molecular mechanisms linking opiates and HIV neurotoxicity, Mocchetti and his team conducted experiments in rats. They found that in the brain, morphine inhibited the toxic property of the HIV protein gp120 that mediates the infection of immune cells. With further investigation, they concluded that morphine induces production of the protein CCL5, which they discovered is released by astrocytes, a type of brain cell. CCL5 is known to activate factors that suppress HIV infection of human immune cells. "It is known to be important in blood, but we didn't know it is secreted in the brain," says Mocchetti. "Our hypothesis is that it is in the brain to prevent neurons from dying."

They say morphine blocked HIV from binding to CCR5 receptors it typically uses to enter and infect cells. The researchers believe CCL5 itself attached to those receptors, preventing the virus from using it. In this way, it prevented HIV-associated dementia. This effect, however, only worked in the M-trophic strain of HIV, the strain that most people are first infected with. It did not work with the second T-trophic strain that often infects patients later.

"Ideally we can use this information to develop a morphine-like compound that does not have the typical dependency and tolerance issues that morphine has," says Mocchetti.

The study was funded by the National Institute on Drug Abuse, part of the National Institutes of Health. Moccetti reports no related financial interests.

About Georgetown University Medical Center

Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through Georgetown's affiliation with MedStar Health). GUMC's mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing and Health Studies, both nationally ranked, the world-renowned Lombardi Comprehensive Cancer Center and the Biomedical Graduate Research Organization (BGRO), home to 60 percent of the university's sponsored research funding. For more information:


Georgetown University Medical Center. Drug Shared by Addicts Seems to Protect against HIV Brain Dementia. Press release. April 15, 2010.